CoChat

Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”

Meltzer, Eli O · 2000 · Annals of Allergy, Asthma & Immunology

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Abstract

Objective This review focuses on the shared pathophysiology of asthma and allergic rhinitis. The similarities illustrate the "one linked airway disease" concept, a unifying theory of these upper and lower airway inflammatory disorders. Since leukotrienes are mediators in both conditions, studies have been performed to assess the potential therapeutic role of cysteinyl leukotriene antagonists. The purpose of this paper is to provide an overview of the accumulating data concerning these agents in treating asthma and allergic rhinitis.Data sources Relevant publications obtained from a literature review.Study selection Relevant publications on the topics of leukotrienes, leukotriene receptor antagonists, asthma, and allergic rhinitis were critically evaluated.Results and conclusions Studies to date have documented the efficacy of cysteinyl leukotriene receptor antagonists for asthma. The pathophysiology of allergic rhinitis and its similarities to asthma suggest that these agents could play a significant therapeutic role in managing this upper airway disorder. Because the leukotriene antagonists are oral agents, they may be valuable in treating not only either condition but also both at the same time when they coexist. They appear to be beneficial when prescribed as the initial medicine and when used in conjunction with other therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1081-1206(10)62750-0

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 70 references

Research works printed but not linked: 12

  1. Baraniuk, 1996, Chronic airway diseases: reassessing the role of allergy, J Respir Dis, 17, S1
  2. Ronberg, 1998, Treatment of allergic rhinitis is associated with lower rates of asthma-related emergency room visits and hospitalizations (Abstract 980), J Allergy Clin Immunol, 101, S236
  3. Barnes, 1998, Should anti-inflammatory agents be used earlier in asthma?, J Respir Dis, 19, S28
  4. Nightingale, 1998, Pharmacokinetics and pharmacodynamics of fluticasone propionate: possible HPA-axis suppression during asthma treatment, Adv Ther, 15, 129
  5. Leff, 1997, Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial (Abstract), Am J Respir Crit Care Med, 155A977
  6. Zhang, 1997, Montelukast, a CysLT1 receptor antagonist, decreases peripheral blood eosinophils and improves signs and symptoms of asthma over a 3 month period (Abstract), J Allergy Clin Immunol, 99, S268
  7. Nathan, 1995, Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) or cromolyn sodium (Intal®) in patients with mild to moderate asthma (Abstract 990), J Allergy Clin Immunol, 95, 388
  8. Nayak, 1998, Addition of zafirlukast compared with a doubled-dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids (Abstract), Eur Respir J, 12, P2388
  9. Knorr, 1998, Selection of a montelukast dose in 2-to 5-year-olds by a comparison of pediatric and adult single-dose pharmacokinetic (PK) profiles (Abstract), Clin Pharmacol Ther, 63, 191A
  10. Ostrom, 1997, Effects of the leukotriene-receptor antagonist zafirlukast on exercise-induced asthma in pediatric subjects (Abstract), Eur Respir J, 10, 276s
  11. Holland, 1998, Montelukast (MON) has no effect on terfenadine (T) pharmacokinetics (PK) or QTc (Abstract), Clin Pharmacol Ther, 63, 232A
  12. Malmstrom, 1998, Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis (Abstract), J Allergy Clin Immunol, 101, S97

Cited by

See all 73

Metadata

Authors
Meltzer, E. O.
Affiliations
Allergy and Asthma Medical Group and Research Center (US)
Corresponding author
Meltzer, Eli O
Venue
Annals of Allergy, Asthma & Immunology
Publisher
Elsevier BV
Published
2000-02
Volume
84
Issue
2
Pages
176-187
ISSN
1081-1206 (ISSN-L)
OpenAlex
W2000134951
Cited by
67
References
72
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 2 · 2012: 2
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Annals of Allergy Asthma & Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Keywords
cysteinyl leukotriene receptor antagonist, asthma, allergic rhinitis, leukotrienes, leukotriene receptor antagonists, upper and lower airway inflammation, shared pathophysiology, combination therapy
MeSH terms
Asthma, Rhinitis, Allergic, Seasonal, Humans, Indoles, Membrane Proteins, Rhinitis, Allergic, Perennial, Sulfonamides, Tosyl Compounds, Receptors, Leukotriene, Leukotriene Antagonists, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. https://app.cochat.ai/papers/10.1016/s1081-1206(10)62750-0
The paper
Meltzer, E. O. (2000). Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/s1081-1206(10)62750-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.